Opko Health Inc (OPK)

[JimProfit]

eXegenics Changes Name to Opko Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Friday June 8, 8:00 am ET

MIAMI, June 8 /PRNewswire-FirstCall/ -- eXegenics, Inc. (OTC Bulletin Board: EXEG - News) today announced that it has completed its name change to Opko Health Inc. The company also announced its common stock has been approved for listing on the American Stock Exchange (AMEX). Opko's stock is expected to begin trading on the AMEX exchange under the ticker symbol OPK on Monday, June 11, 2007.

"Now that we are officially Opko Health, it is fitting that our shares have been approved for listing on the American Stock Exchange," said Dr. Philip Frost, chairman and CEO of Opko Health, Inc. "The improved visibility and liquidity available to us as an AMEX-listed company should contribute to our efforts to advance our ophthalmic businesses and build shareholder value."

This approval is contingent upon Opko being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if the company is not in compliance with such standards.

About Opko Health

Miami-based Opko Health was recently reconstituted as a specialty healthcare company through a 3-way merger of eXegenics, Inc. with private companies Acuity Pharmaceuticals Inc., and Froptix, Inc. Its product portfolio includes the pioneering gene silencing agent bevasiranib, which has successfully completed Phase ll clinical trials for wet age-related macular degeneration and diabetic macular edema; a novel clinical stage product for conjunctivitis; and a pipeline of preclinical candidates that include novel agents to treat dry age-related macular degeneration and other ophthalmic diseases. The company also intends to market selected diagnostic products that are complementary to its therapeutic programs.

Source: Opko Health